- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06272864
BostonGene en Exigent Genomic INsight-onderzoek (BEGIN)
BostonGene en Exigent Genomic INsight (BEGIN) studie: een prospectieve studie van uitgebreide moleculaire testen bij gevorderde kankerpatiënten in de gemeenschapssetting
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
The BEGIN Study, conducted by BostonGene and Exigent, is a prospective investigation aimed at evaluating the efficacy and feasibility of comprehensive molecular testing in advanced cancer patients within the community setting. Recent advancements in cancer treatment have led to the integration of targeted and immune-based therapies into standard practice. Recognizing the significance of genomic and molecular alterations in patient therapy selection, BostonGene has developed a high-throughput sequencing platform, the BostonGene Tumor Portrait test, which provides a comprehensive overview of tumors and their microenvironment.
The primary objectives of the study include determining the frequency of actionable findings identified by the BostonGene Tumor Portrait test, assessing the feasibility and turnaround time of comprehensive sequencing analysis, and evaluating the frequency of patient enrollment in clinical trials based on test results. Secondary objectives involve determining the frequency of patients receiving molecularly matched therapy, evaluating concordance between DNA and RNA targets, and assessing the impact of test findings on treatment decisions.
The study will involve four cohorts of patients with breast cancer, non-small cell lung cancer, melanoma, and sarcoma, each comprising 100 participants. Subjects will be identified through designated pilot sites. The study duration will be up to two years, with data collection including baseline demographics, medical history, treatment decisions, and patient outcomes.
Overall, the study aims to elucidate the clinical utility of the BostonGene Tumor Portrait test in guiding treatment decisions for advanced cancer patients in real-world community settings, with a focus on actionable findings, treatment efficacy, and patient outcomes.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Nathan Fowler, MD
- Telefoonnummer: 781-552-3131
- E-mail: nathan.fowler@bostongene.com
Studie Locaties
-
-
Arkansas
-
Rogers, Arkansas, Verenigde Staten, 72758
- Werving
- Highlands Oncology Group
-
Hoofdonderzoeker:
- Eric Schaefer, MD
-
Contact:
- Adam Torres
- E-mail: ATorres@hogonc.com
-
-
California
-
Stockton, California, Verenigde Staten, 95204
- Werving
- Stockton Hematology Oncology Medical Group
-
Hoofdonderzoeker:
- Dheeraj Kodali, MD
-
Contact:
- Lizbeth Ortiz
- E-mail: lortiz@shomg.net
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87109
- Werving
- New Mexico Cancer Center
-
Contact:
- Valerie Tucker
- E-mail: valeriet@nmohc.com
-
Hoofdonderzoeker:
- Katherine Sanchez, MD
-
-
Oklahoma
-
Tulsa, Oklahoma, Verenigde Staten, 74146
- Werving
- Oklahoma Cancer Specialists and Research Institute
-
Hoofdonderzoeker:
- Paul Zito, MD
-
Contact:
- Ruth Dunn
- E-mail: ruth.dunn@ocsri.org
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Oncology Consultants
-
Hoofdonderzoeker:
- Julio Peguero, MD
-
Contact:
- Laura Guerra
- E-mail: lguerra@OncologyConsultants.com
-
-
Washington
-
Puyallup, Washington, Verenigde Staten, 98373
- Werving
- Northwest Medical Specialities
-
Contact:
- Malee Chhan
- E-mail: mchhan@nwmsonline.com
-
Hoofdonderzoeker:
- Sibel Blau, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Advanced cancer patients
Beschrijving
Inclusion Criteria:
- Patients must have a confirmed malignancy of:
Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.
- Life expectancy > 3 months as per the treating physician
- Willingness to provide informed consent
- Living in the United States at time of enrollment
- Agree to participate in genomic and molecular profiling
Exclusion Criteria:
- not meeting the inclusion criteria
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Breast cancer
Patients with locally recurrent, unresectable or metastatic breast cancer |
|
NSCLC
Patients with unresectable stage III or metastatic non-small cell lung cancer |
|
Melanoma
Patients with unresectable or metastatic melanoma |
|
Sarcoma
Patients with locally advanced or metastatic sarcoma |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency of actionable findings
Tijdsspanne: 2 years
|
the frequency of actionable findings identified by a comprehensive (WES/RNA) sequencing platform (BostonGene Tumor Portrait) in advanced cancer patients. Actionable findings will include: genomic findings such as fusions, single nucleotide variants (SNVs), insertion/deletion alterations (indels), copy number alterations (CNAs), tumor mutational burden (TMB), microsatellite instability (MSI), frameshifts, rearrangements, gene expression levels, genome instability and loss of heterozygosity, cell counts in TME, disease molecular type, inherited pathogenic mutations, mutational signatures, and gene isoform expression. |
2 years
|
|
Test turn-around time
Tijdsspanne: 2 years
|
the time from consent to biopsy (or archival tissue retrieval), time from receipt of biopsy to BostonGene Tumor Portrait testing results, and total time from consent to delivery of BostonGene Tumor Portrait testing resultsTumor Portrait testing |
2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency of patients who receive molecularly matched therapy
Tijdsspanne: 6 months
|
the frequency of patients who receive molecularly matched therapy within 6 months of undergoing genomic testing |
6 months
|
|
Frequency of patients who receive molecularly matched therapy
Tijdsspanne: 12 months
|
the frequency of patients who receive molecularly matched therapy within 12 months of undergoing genomic testing |
12 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Longziekten
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Huidziektes
- Borst ziekten
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Neuro-endocriene tumoren
- Neoplasmata, bindweefsel en zacht weefsel
- Nevi en melanomen
- Huidneoplasmata
- Huid- en bindweefselaandoeningen
- Borstneoplasmata
- Carcinoom, niet-kleincellige long
- Melanoma
- Sarcoom
Andere studie-ID-nummers
- BEGIN study
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .